The words "OMICRON SARS-COV-2" are seen reflected in a drop from a syringe needle in this illustration taken December 11, 2021. - Reuters
BEIJING, April 30 (Reuters): China's Suzhou Abogen Biosciences Co said its Covid-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.
With Friday's announcement, Abogen joins Pfizer/BioNTech and Moderna in trialing candidates modified specifically against Omicron, a highly transmissible variant with increased resistance to antibodies elicited by existing shots.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
